2023-10-012024-09-302024-09-30false12231789SAGE THERAPY CENTRE LIMITED2025-04-01falseiso4217:GBPxbrli:pure122317892023-10-01122317892024-09-30122317892023-10-012024-09-30122317892022-10-01122317892023-09-30122317892022-10-012023-09-3012231789bus:SmallEntities2023-10-012024-09-3012231789bus:AuditExempt-NoAccountantsReport2023-10-012024-09-3012231789bus:FullAccounts2023-10-012024-09-3012231789bus:PrivateLimitedCompanyLtd2023-10-012024-09-3012231789core:WithinOneYear2024-09-3012231789core:AfterOneYear2024-09-3012231789core:WithinOneYear2023-09-3012231789core:AfterOneYear2023-09-3012231789core:ShareCapital2024-09-3012231789core:SharePremium2024-09-3012231789core:RevaluationReserve2024-09-3012231789core:OtherReservesSubtotal2024-09-3012231789core:RetainedEarningsAccumulatedLosses2024-09-3012231789core:ShareCapital2023-09-3012231789core:SharePremium2023-09-3012231789core:RevaluationReserve2023-09-3012231789core:OtherReservesSubtotal2023-09-3012231789core:RetainedEarningsAccumulatedLosses2023-09-3012231789core:LandBuildings2024-09-3012231789core:PlantMachinery2024-09-3012231789core:Vehicles2024-09-3012231789core:FurnitureFittings2024-09-3012231789core:OfficeEquipment2024-09-3012231789core:NetGoodwill2024-09-3012231789core:IntangibleAssetsOtherThanGoodwill2024-09-3012231789core:ListedExchangeTraded2024-09-3012231789core:UnlistedNon-exchangeTraded2024-09-3012231789core:LandBuildings2023-09-3012231789core:PlantMachinery2023-09-3012231789core:Vehicles2023-09-3012231789core:FurnitureFittings2023-09-3012231789core:OfficeEquipment2023-09-3012231789core:NetGoodwill2023-09-3012231789core:IntangibleAssetsOtherThanGoodwill2023-09-3012231789core:ListedExchangeTraded2023-09-3012231789core:UnlistedNon-exchangeTraded2023-09-3012231789core:LandBuildings2023-10-012024-09-3012231789core:PlantMachinery2023-10-012024-09-3012231789core:Vehicles2023-10-012024-09-3012231789core:FurnitureFittings2023-10-012024-09-3012231789core:OfficeEquipment2023-10-012024-09-3012231789core:NetGoodwill2023-10-012024-09-3012231789core:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3012231789core:ListedExchangeTraded2023-10-012024-09-3012231789core:UnlistedNon-exchangeTraded2023-10-012024-09-3012231789core:MoreThanFiveYears2023-10-012024-09-3012231789core:Non-currentFinancialInstruments2024-09-3012231789core:Non-currentFinancialInstruments2023-09-3012231789dpl:CostSales2023-10-012024-09-3012231789dpl:DistributionCosts2023-10-012024-09-3012231789core:LandBuildings2023-10-012024-09-3012231789core:PlantMachinery2023-10-012024-09-3012231789core:Vehicles2023-10-012024-09-3012231789core:FurnitureFittings2023-10-012024-09-3012231789core:OfficeEquipment2023-10-012024-09-3012231789dpl:AdministrativeExpenses2023-10-012024-09-3012231789core:NetGoodwill2023-10-012024-09-3012231789core:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3012231789dpl:GroupUndertakings2023-10-012024-09-3012231789dpl:ParticipatingInterests2023-10-012024-09-3012231789dpl:GroupUndertakingscore:ListedExchangeTraded2023-10-012024-09-3012231789core:ListedExchangeTraded2023-10-012024-09-3012231789dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-10-012024-09-3012231789core:UnlistedNon-exchangeTraded2023-10-012024-09-3012231789dpl:CostSales2022-10-012023-09-3012231789dpl:DistributionCosts2022-10-012023-09-3012231789core:LandBuildings2022-10-012023-09-3012231789core:PlantMachinery2022-10-012023-09-3012231789core:Vehicles2022-10-012023-09-3012231789core:FurnitureFittings2022-10-012023-09-3012231789core:OfficeEquipment2022-10-012023-09-3012231789dpl:AdministrativeExpenses2022-10-012023-09-3012231789core:NetGoodwill2022-10-012023-09-3012231789core:IntangibleAssetsOtherThanGoodwill2022-10-012023-09-3012231789dpl:GroupUndertakings2022-10-012023-09-3012231789dpl:ParticipatingInterests2022-10-012023-09-3012231789dpl:GroupUndertakingscore:ListedExchangeTraded2022-10-012023-09-3012231789core:ListedExchangeTraded2022-10-012023-09-3012231789dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-10-012023-09-3012231789core:UnlistedNon-exchangeTraded2022-10-012023-09-3012231789core:NetGoodwill2024-09-3012231789core:IntangibleAssetsOtherThanGoodwill2024-09-3012231789core:LandBuildings2024-09-3012231789core:PlantMachinery2024-09-3012231789core:Vehicles2024-09-3012231789core:FurnitureFittings2024-09-3012231789core:OfficeEquipment2024-09-3012231789core:AfterOneYear2024-09-3012231789core:WithinOneYear2024-09-3012231789core:ListedExchangeTraded2024-09-3012231789core:UnlistedNon-exchangeTraded2024-09-3012231789core:ShareCapital2024-09-3012231789core:SharePremium2024-09-3012231789core:RevaluationReserve2024-09-3012231789core:OtherReservesSubtotal2024-09-3012231789core:RetainedEarningsAccumulatedLosses2024-09-3012231789core:NetGoodwill2023-09-3012231789core:IntangibleAssetsOtherThanGoodwill2023-09-3012231789core:LandBuildings2023-09-3012231789core:PlantMachinery2023-09-3012231789core:Vehicles2023-09-3012231789core:FurnitureFittings2023-09-3012231789core:OfficeEquipment2023-09-3012231789core:AfterOneYear2023-09-3012231789core:WithinOneYear2023-09-3012231789core:ListedExchangeTraded2023-09-3012231789core:UnlistedNon-exchangeTraded2023-09-3012231789core:ShareCapital2023-09-3012231789core:SharePremium2023-09-3012231789core:RevaluationReserve2023-09-3012231789core:OtherReservesSubtotal2023-09-3012231789core:RetainedEarningsAccumulatedLosses2023-09-3012231789core:NetGoodwill2022-10-0112231789core:IntangibleAssetsOtherThanGoodwill2022-10-0112231789core:LandBuildings2022-10-0112231789core:PlantMachinery2022-10-0112231789core:Vehicles2022-10-0112231789core:FurnitureFittings2022-10-0112231789core:OfficeEquipment2022-10-0112231789core:AfterOneYear2022-10-0112231789core:WithinOneYear2022-10-0112231789core:ListedExchangeTraded2022-10-0112231789core:UnlistedNon-exchangeTraded2022-10-0112231789core:ShareCapital2022-10-0112231789core:SharePremium2022-10-0112231789core:RevaluationReserve2022-10-0112231789core:OtherReservesSubtotal2022-10-0112231789core:RetainedEarningsAccumulatedLosses2022-10-0112231789core:AfterOneYear2023-10-012024-09-3012231789core:WithinOneYear2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:CostValuation2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-10-012024-09-3012231789core:Non-currentFinancialInstrumentscore:CostValuation2024-09-3012231789core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-3012231789core:Non-currentFinancialInstrumentscore:CostValuation2023-09-3012231789core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-3012231789core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-3012231789core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-3012231789core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-3012231789core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-3012231789core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-3012231789core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-3012231789core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-3012231789bus:Director12023-10-012024-09-3012231789core:FurnitureFittingsToolsEquipment2023-09-3012231789core:FurnitureFittingsToolsEquipment2023-10-012024-09-3012231789core:FurnitureFittingsToolsEquipment2024-09-30

SAGE THERAPY CENTRE LIMITED

Registered Number
12231789
(England and Wales)

Unaudited Financial Statements for the Year ended
30 September 2024

SAGE THERAPY CENTRE LIMITED
Company Information
for the year from 1 October 2023 to 30 September 2024

Director

CORPE, Natalie Elizabeth

Registered Address

635 Western Boulevard
Nottingham
NG8 5GS

Registered Number

12231789 (England and Wales)
SAGE THERAPY CENTRE LIMITED
Balance Sheet as at
30 September 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets47,55714,164
7,55714,164
Current assets
Debtors54,5823,823
Cash at bank and on hand24,70612,963
29,28816,786
Creditors amounts falling due within one year6(12,419)(20,135)
Net current assets (liabilities)16,869(3,349)
Total assets less current liabilities24,42610,815
Provisions for liabilities7(486)-
Net assets23,94010,815
Capital and reserves
Called up share capital11
Profit and loss account23,93910,814
Shareholders' funds23,94010,815
The financial statements were approved and authorised for issue by the Director on 1 April 2025, and are signed on its behalf by:
CORPE, Natalie Elizabeth
Director
Registered Company No. 12231789
SAGE THERAPY CENTRE LIMITED
Notes to the Financial Statements
for the year ended 30 September 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Fixtures and fittings5
Office Equipment5
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
2.Average number of employees

20242023
Average number of employees during the year33
3.Deferred tax
Increases in the UK Corporation tax rate from 19% to 25% (19% effective from 1 April 2017, and 25% effective from 1 April 2023) have been substantively enacted. This will impact the company's future tax charge accordingly. The value of the deferred tax assets at the balance sheet date has been calculated using the applicable rate when the asset is expected to be realised.
4.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 October 2325,00013,27038,270
Additions-1,3101,310
Disposals-(1,633)(1,633)
At 30 September 2425,00012,94737,947
Depreciation and impairment
At 01 October 2315,0009,10624,106
Charge for year5,0002,4367,436
On disposals-(1,152)(1,152)
At 30 September 2420,00010,39030,390
Net book value
At 30 September 245,0002,5577,557
At 30 September 2310,0004,16414,164
5.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables4,5823,396
Other debtors-427
Total4,5823,823
6.Creditors: amounts due within one year

2024

2023

££
Bank borrowings and overdrafts589252
Amounts owed to related parties6,92919,883
Taxation and social security4,901-
Total12,41920,135
7.Provisions for liabilities

2024

2023

££
Net deferred tax liability (asset)486-
Total486-
8.Related party transactions
During the year interest free loans were made available to the directors, these totalled £6,929 at the year end (2023: £19,884)